Nephrology Department at Shanghai General Hospital Conducts Immunoadsorption Therapy for the First Case of Severe Systemic Lupus Erythematosus in Songjiang District

Link of the orginial article:https://mp.weixin.qq.com/s/HOeFQhTxQEnyC7PfIFOqTA

Systemic lupus erythematosus (SLE) is an autoimmune disease that involves multiple system organs and has complex clinical manifestations, and has a prolonged and recurrent course. If not treated in a timely manner, it can endanger the patient's life. At present, hormone, immunosuppressive agents, and biologic therapy are commonly used in clinical practice for treatment. However, some severe SLE patients have poor clinical prognosis due to rapid disease progression and poor treatment response. Recently, the Southern Department of Nephrology of Shanghai General Hospital successfully implemented DNA plasma immunoadsorption technology for a patient with severe systemic lupus erythematosus and Lupus nephritis, and achieved good results. This is the first case of DNA plasma immunoadsorption therapy carried out by a hospital in Shanghai General Hospital and in Songjiang area

The patient receiving treatment this time was a 50 year old female who was diagnosed with systemic lupus erythematosus (severe activity) and Lupus nephritis in our hospital and admitted to the nephrology ward. In order to effectively alleviate the progression of his disease, the medical team from the Southern Renal Department and Hemodialysis Room of Shanghai General Hospital has developed a treatment plan for him called "DNA Plasma Immunoadsorption" through repeated literature review and thorough communication and discussion. 

On June 9, on the basis of high-dose hormone shock combined with Immunosuppressive drug, anti-infection and symptomatic support treatment, the medical team in the nephrology department and hemodialysis room implemented the first DNA plasma immunoadsorption treatment for patients. After three rounds of immunosorbent therapy, the patient's symptoms such as choking sensation in chest, headache, edema, and skin erythema have significantly improved, and various antibody indicators have decreased. The condition has improved significantly and has now been discharged smoothly.

According to Prof. Qing Yu, director of the Department of Nephrology (South), DNA plasma immunoadsorption therapy uses the principle of immune reaction, uses highly purified DNA molecular fragments as ligands, and is fixed on the carbonized resin coated with a special capsule. It can specifically identify and absorb highly pathogenic Autoantibody in patients, reduce the titers of Antinuclear antibody (ANA) and anti ds-DNA antibodies, and remove pathogenic immune active substances in the body, so as to effectively control the condition of critically ill patients. This time, the Southern Nephrology Department carried out the first DNA immunosorbent therapy, filling the gap in our hospital's treatment technology and providing a new path for the treatment of severe lupus patients. 

Correspondents: Dr.Yanhua Jiang, Dr.Lijun Wang,Renal Hemodialysis Room